CX-2051 demonstrated a 28% overall response rate in advanced colorectal cancer, with a 43% response at the highest dose of 10 mg/kg. The disease control rate was 94%, and median progression-free ...

May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced positive interim Phase 1 data for its ...

Abstract: A novel integrated high-voltage linear power amplifier for medical ultrasonic transmitter applications is presented in this brief. The amplifier employs a current-feedback technique with two ...